PepGen voluntarily pauses Phase 2 CONNECT2-EDO51 study; awaits 10 mg/kg data from CONNECT1

PepGen Inc.

Temporarily pauses CONNECT2-EDO51 in DMD until review of 10 mg/kg data from ongoing CONNECT1-EDO51 study.
No new safety issues observed in PGN-EDO51 program since safety update on January 23, 2025.
CONNECT1 10 mg/kg cohort fully enrolled; data expected in third quarter of 2025.
Resources focused on completing CONNECT1 and advancing FREEDOM-DM1 studies in myotonic dystrophy type 1.
CEO states pause allows gathering additional safety data and potential improvement of CONNECT2 design.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.